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Functionally different α-synuclein 
inclusions yield insight into 
Parkinson’s disease pathology
Christian C. Raiss1, Theresa S. Braun1, Irene B. M. Konings1, Heinrich Grabmayr4, 
Gerco C. Hassink2, Arshdeep Sidhu1, Joost le Feber2, Andreas R. Bausch4, Casper Jansen3, 
Vinod Subramaniam1,5 & Mireille M. A. E. Claessens1
The formation of α-synuclein (α-S) amyloid aggregates, called Lewy bodies (LBs), is a hallmark of 
Parkinson’s disease (PD). The function of LBs in the disease process is however still unclear; they have 
been associated with both neuroprotection and toxicity. To obtain insight into this contradiction, we 
induced the formation of α-S inclusions, using three different induction methods in SH-SY5Y cells 
and rat-derived primary neuronal cells. Using confocal and STED microscopy we observed induction-
dependent differences in α-S inclusion morphology, location and function. The aggregation of α-S in 
functionally different compartments correlates with the toxicity of the induction method measured in 
viability assays. The most cytotoxic treatment largely correlates with the formation of proteasome-
associated, juxta-nuclear inclusions. With less toxic methods cytosolic deposits that are not associated 
with the proteasome are more prevalent. The distribution of α-S over at least two different types of 
inclusions is not limited to cell models, but is also observed in primary neuronal cells and in human 
mesencephalon. The existence of functionally different LBs, in vivo and in vitro, gives important insights 
in the impact of Lewy Body formation on neuronal functioning and may thereby provide a platform for 
discovering therapeutics.
The aggregation of soluble proteins into insoluble, β -sheet-rich amyloid fibrils is characteristic for many neu-
rodegenerative diseases. Intraneuronal aggregates of α -synuclein (α -S) are for example found in Parkinson’s 
disease (PD), Lewy body dementia and multiple system atrophy1–3. Whereas extracellular β -amyloid deposits 
and intracellular accumulations of phosphorylated tau protein occur in Alzheimer’s disease4,5. In Huntington’s 
disease, polyglutamine-expanded huntingtin (htt) protein accumulates within intranuclear inclusion bodies or 
neurites6 and in amyotrophic lateral sclerosis, motor neurons develop protein-rich inclusions containing superox-
ide dismutase 1, TAR DNA-binding protein 43 or the RNA-binding protein fused-in-sarcoma in their cell bodies 
and axons7–10.
In PD, α -S amyloid inclusions such as Lewy neurites (LN) and Lewy bodies (LB) can be found in neurons 
and glia cells2,3,11. The topographical progression of neuronal death, and the development of α -S immunore-
active Lewy body related structures12,13, here abbreviated to Lewy body like inclusions (LBLI), throughout the 
brain is used to stage PD pathology14. The pathologically determined stages are in many cases related to clinical 
features observed in patients15. Nevertheless, the role of LBLI during the progression of PD is unclear. LBLI may 
be indicative of cellular dysfunction and death16,17 but have also been described as harmless, inert or neuropro-
tective protein aggregates18. PD symptoms have been shown to directly correlate with the density of neurons in 
the substantia nigra pars compacta19, but no correlation could be established between the number of LBLI and 
the severity of disease symptoms16. Assuming LBLI are indeed inert, one would expect the affected cells to have 
a normal life span. With the loss of other cells in the tissue19, the proportion of cells with LBLI should therefore 
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increase. However, recent studies show that in the brain of PD patients the proportion of cells with such inclu-
sions is constant17. It is therefore likely that LBLI do play a role in neuronal death. Yet surprisingly, LBLI are also 
observed in individuals not showing PD symptoms20,21. Thus, the role of these inclusions in the progression of 
PD is disputed, and the question remains if LBLI are toxic or the effect of a neuroprotective response to possibly 
toxic protein misfolding.
Recent studies propose that the process of protein aggregation is regulated and misfolded proteins are 
sequestered to inclusion sites with distinct functions22. In protein aggregation studies in cell model systems, 
two intracellular compartments for the sequestration of misfolded cytosolic proteins were identified: the JUxta 
Nuclear Quality control compartment (JUNQ) and the insoluble protein deposit (IPOD)23. The JUNQ inclu-
sion site is located adjacent to the nucleus. It encloses soluble, ubiquitinated, misfolded proteins and chaperones 
mediating refolding or degradation. The JUNQ compartment is used to temporarily store misfolded proteins. 
Amyloidogenic proteins that cannot be degraded or refolded are sequestered to the IPOD. The degradation or 
refolding of proteins in the JUNQ can be hampered when it becomes saturated with insoluble aggregates23. It has 
been demonstrated that when this happens JUNQ inclusions turn neurotoxic24.
Here, we induced α -S aggregation and the formation of α -S inclusions in a cell model system to comprehend 
the possible origin of toxicity or protection of α -S amyloid inclusions. We used three different induction protocols 
which resulted in significantly different cytotoxicity. We demonstrate a dependence of α -S inclusion morphology 
and location on induction method and show, to the best of our knowledge for the first time, that α -S can sequester 
to- and aggregate in- functionally different compartments in vivo and in vitro. We hypothesize that accumulation 
of α -S in these different cellular compartments determines cell fate and sheds light on the disputed role of LBLIs 
in PD.
Results
In vitro expressed α-S-GFP can be incorporated in amyloid fibrils. To enable visualization of 
α -S distribution and aggregation in SH-SY5Y cells, α -S was tagged with green fluorescent protein (α -S-GFP). 
To exclude the possibility that the attached GFP-tag hinders α -S fibrillization, the fibril-forming properties of 
α -S-GFP were assessed in vitro. For this purpose, recombinant α -S-GFP was expressed in E. coli (Fig. S1), isolated 
and tested for fibrillization. At physiological salt concentrations, purified-untagged, recombinantly expressed 
α -S assembles into amyloid fibrils25–27. Fibrillization could not be observed for pure α -S-GFP or 1:1 ratios of 
tagged and untagged α -S. After 3 days of incubation in a 1:10 ratio however, α -S-GFP fibrils were clearly detect-
able by fluorescence microscopy. A control experiment in which untagged α -S was aggregated and labelled with 
Thioflavin T indicates that compared to fibrils of untagged α -S the α -S-GFP containing fibrils may be shorter 
(Fig. S2). Under the experimental conditions used, long time incubation of GFP alone did not result in fibril 
formation (data not shown).
α-S-GFP expression in cells. To effectively visualize the distribution of α -S monomers and aggregates 
inside SH-SY5Y cells, an α -S-GFP fusion construct was stably transfected. Both untagged-endogenous and 
GFP-tagged α -S were detected by Western blot analysis of total lysate from differentiated α -S-GFP SH-SY5Y cells 
(Fig. S3A). Total lysate from control SH-SY5Y cells without the fusion construct only contained untagged α -S. 
In the stably transfected cells, endogenous-untagged α -S was present in amounts close to the detection limit and 
could only be observed by increasing the contrast of the blots significantly. α -S-GFP from the transfected con-
struct was clearly visible (see Supplementary Fig. S3A). No free GFP could be detected in the cell lysates (Fig. S4). 
Fluorescence microscopy of α -S-GFP SH-SY5Y cells showed that all cells express α -S-GFP. However, differ-
ent α -S-GFP fluorescence intensities were observed in the cell population (see Supplementary Fig. S3B). The 
differences in intensities were attributed to different expression levels of α -S-GFP and therefore probably dif-
ferent ratios of untagged α -S to α -S-GFP. We observed a diffuse distribution of α -S-GFP throughout the cells. 
Immunolabelling of α -S showed both a cytosolic and an intranuclear expression pattern (see Supplementary Fig. 
S3C). Further, we were interested in the effect of α -S-GFP on cell morphology. Visualization of the actin network 
with fluorescently tagged phalloidin in control cells and cells expressing α -S-GFP did however not reveal notable 
differences (data not shown).
α-S seeds nucleate α-S aggregation in vitro. The expression of α -S or α -S-GFP in SH-SY5Y cells did 
not by itself result in the formation of α -S inclusion bodies on the time scales studied. One way to initiate α -S 
monomer aggregation and shorten the aggregation lag time, is adding seeds to a pool of monomeric α -S pro-
tein28. In cells, α -S-fibril seeds may recruit cytoplasmic soluble α -S proteins and convert them to the insoluble 
β -sheet rich fibrils. Hence, we produced α -S seeds by sonication of pre-aggregated α -S fibrils. The resulting fibril 
fragments were characterized using tapping mode atomic force microscopy (AFM). The obtained AFM images 
show a population of fibrils with lengths up to 500 nm (see Supplementary Fig. S5A). To evaluate the potency of 
the created α -S seeds to initiate α -S aggregation, we added them to a pool of monomeric α -S and followed amy-
loid formation in a Thioflavin T (ThioT) fluorescence assay. The control containing only α -S monomers did not 
show aggregation in the first 24 hours (see Supplementary Fig. S5B). The addition of fibril seeds circumvented the 
slow formation of aggregation prone nuclei. Amyloid growth started immediately after seed addition.
To be able to initiate α -S aggregation inside cells, α -S seeds must be internalized and come in contact with the 
endogenous α -S pool. Previous studies have shown that amyloid fibrils can be internalized by cells after addition 
to culture medium29–32. Accordingly, we administered α -S seeds to the cell medium. Using confocal microscopy, 
we mainly observed attachment of α -S fibril clusters to the outer cell membrane. A fraction of the fibril clusters 
was internalized within the first 12 hours (see Supplementary Fig. S6). We further observed that intracellular 
inclusion formation could be nucleated by internalized α -S fibrils. In wild type SH-SY5Y cells, we observed α -S 
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inclusions formed around the internalized fluorescently-labelled α -S seeds. The seeds apparently served as a 
nucleation site to which endogenous α -S was recruited (Fig. 1).
α-S inclusion characteristics and morphology. Besides the addition of 500 nM α -S seeds we used two 
other approaches to induce the formation of α -S inclusions in SH-SY5Y cells: i) addition of 100 μM α -S mono-
mers, and ii) exposure to 5 nM rotenone33. We compared the induction approaches at time points where, upon 
visual inspection, comparable fractions of the cells contained α -S inclusions. For α -S inclusions induction using 
α -S monomers and α -S seeds this was usually after 5 days while cultures needed to be exposed to rotenone 
for 4 weeks to obtain a comparable fraction of α -S inclusions. The thus obtained inclusionts were comparable 
Figure 1. α-S-seeds nucleate the formation of α-S inclusions in SH-SY5Y cells. Differentiated SH-SY5Y 
cells were exposed to 500 nM fluorescently labelled α -S seeds (α -S-seedsThioT: blue) and immunostained for α -S 
(α -Salexa594: green). After this treatment, the α -S was, in some cells, no longer homogenously distributed over 
the cell volume but concentrated in micrometer sized inclusions. A magnification of the inclusion shows that 
α -S-seedsThioT were taken up by the cell and form the core of an inclusion . Scale bar: 3 μm, STED microscopy.
Figure 2. Induced α-S inclusions show key features of LBLIs. (A) LBLIs in human mesencephalon derived 
from a PD patient and α -S inclusions in α -S-GFP SH-SY5Ycells both contain α -S, are comparable in size, 
α -S density and morphology; grey: α -Salexa594, STED microscopy; scale bar: 0.5 μm. (B) Haematoxylin/Eosin 
staining reveals eosinophilic oval α -S inclusions in α -S-GFP SH-SY5Y cells; an inclusion is indicated by the red 
arrow, bright field microscopy, scale bar: 10 μm. (C) α -S in inclusions is phosphorylated and binds ThioS; green: 
α -S-GFP, purple: α -S pSer129alexa555, red: ThioS, α -S inclusions indicated by white arrow, scale bar: 10 μm.  
(D) Different inclusion morphologies (hairy, amorph, tangle, fibrillar, round) were observed in different cellular 
locations; α -S-GFP (green), actinalexa647 (red); nuclei are indicated by the dashed lines; confocal images, scale 
bar: 10 μm.
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in size and morphology to LBLI observed in vivo (Fig. 2A) and displayed key features of LBs and LNs, such as 
phosphorylation of α -S and eosinophilia (Fig. 2B,C). Additionally, we observed Thioflavin S (ThioS) binding 
to the α -S inclusions, indicating that they consist of cross-beta sheet fibrils (Fig. 2C) The morphology of the 
α -S inclusions obtained varied from LB-like spherical inclusions to spindle or thread like aggregates resembling 
LNs. The inclusions differed in α -S density and distribution and were observed in both the cell body and cell 
extensions (Fig. 2D). The morphology of α -S inclusions found in differentiated α -S-GFP SH-SY5Y cells was 
comparable to those present in differentiated wild type SH-SY5Y cells and rat primary neuronal cells (data not 
shown). Similar α -S inclusion morphologies were observed in in vivo in human brain (see Supplementary Fig. 
S7). Neuropathological α -S inclusions are often difficult to characterize into e.g. classical Lewy bodies, cortical 
Lewy bodies and pale bodies. The outcome of such a characterization depends on the treatment and antibodies 
used and additionally there is a huge inter-observer variability12,13. To circumvent ambiguities we therefore classi-
fied all the α -S inclusions and quantified differences in morphology and location using physical parameters (see 
Materials and Methods).
Interestingly, the obtained α -S inclusion morphology and location in the cells differed between the three 
induction methods. Generally, α -S inclusions induced by the addition of α -S monomers were spherical and often 
localized near the cell nucleus. Treatment with rotenone mainly resulted in oval/kidney-like morphologies with 
well-defined borders. After exposure to fibrillar α -S seeds, a considerable fraction of cells contained cytoplasmic 
thread-like, radiating fibrillar or less dense and diffuse inclusions. Such hairy inclusions were largely absent after 
the other induction approaches. Similar results were obtained for wild type SH-SY5Y cells, α -S-GFP SH-SY5Y 
cells (Fig. 3A) and primary neuronal cells (see Supplementary Fig. S8).
To quantify the different shapes, we classified the obtained α -S inclusions based on their morphology and 
their proximity to the nucleus. Figure 3A summarizes the distribution of the observed inclusion morphologies in 
wild type SH-SY5Y and α -S-GFP SH-SY5Y cells for all three induction treatments. The morphologies were clas-
sified in round, oval/kidney-like, amorphous or hairy (fibrillar threads). Most inclusions induced by α -S mono-
mers were round (50%), with smaller fractions of oval (26%) and amorphous (17%) LBLIs. We could only find a 
minor fraction of hairy inclusions (7%). After treatment with α -S seeds comparable amounts of all α -S inclusion 
morphologies were found: round 24%, oval 29%, amorphous 29%, hairy 17%. Induction of α -S inclusion forma-
tion with rotenone mainly resulted in oval inclusions (63%). The remainder of the inclusions found after rotenone 
treatment were round (20%) or amorphous (17%); hardly any hairy inclusions were present.
The different induction methods not only influenced α -S inclusions morphology, but also the cellular loca-
tion of the inclusions. We therefore also classified inclusions by their proximity to the cell’s nucleus. In contrast 
to the induction with rotenone where only 11% of all inclusions were found in proximity of the nucleus, 44% of 
all inclusions formed after treatment with α -S seeds or α -S monomers were found close to the nucleus (Fig. 3B). 
Further, we determined which α -S inclusion morphology was most likely found close to the nucleus. 78% of 
the α -S deposits located in proximity of the cell’s nucleus were round or oval/kidney-like. In contrast, 83% of 
Figure 3. The induction method determines α-S inclusion morphology and proximity to the nucleus. 
(A) α -S inclusions were induced in SH-SY5Y cells and α -S-GFP SH-SY5Ycells with rotenone (blue, N = 58), 
α -S monomers (green, N = 46), α -S seeds (red, N = 46) and categorized based on their morphology (round, 
oval, amorphous, hairy). For each condition 20 inclusions in GFP-SH-SY5Y cells were taken into account, 
the remainder of the data was obtained in SH-SY5Y cells. α -S inclusions induced by α -S monomers are 
predominantly round (50%). When treated with α -S seeds, all inclusion morphologies appear in a comparable 
amount. Induction with rotenone mainly results in oval inclusions (63%). (B) Approximately 44% of the α -S 
inclusions induced with α -S monomers (green) and α -S seeds (red) are juxtanuclear (N = 36). After treatment 
with rotenone (blue) only 11% of the inclusions are found close to the nucleus. (C) α -S inclusion morphology is 
a good predictor for inclusion location in the cell. Most juxtanuclear inclusions are either round or oval/kidney-
like (78%). The probability for amorphous (17%) and hairy (6%) α -S inclusions to be close to the nucleus is low.
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amorphous inclusions and 94% of hairy α -S deposits were found further away from the nucleus, in the cytoplasm 
(Fig. 3C). We speculate that different factors like the availability of endogenous α -S, crowding, or colocalization 
with other proteins and cellular structures may define the α -S inclusion morphologies. Especially after induction 
with α -S seeds a relatively large fraction of inclusions with a hairy morphology was observed. These fibrillar α -S 
accumulations span the cytoplasm and might have developed along cytoskeletal networks.
α-S sequesters in functionally different α-S inclusions. Intracellular protein aggregation is con-
sidered a well-managed process23,34. In this context, two intracellular inclusion sites were described: the 
“juxta-nuclear quality control” compartment (JUNQ) is an intracellular region in which soluble misfolded pro-
teins concentrate to be re-folded by chaperones or to be prepared for degradation by the proteasome. Insoluble 
and non-degradable amyloids are sequestered to the cytoplasmic “insoluble protein deposit” (IPOD). These inclu-
sion sites can be distinguished by their colocalization with distinct proteins. The chaperone heat shock proteins 70 
(hsp70) and the proteasome subunit low molecular mass protein 2 (lmp2) are both typically active in the JUNQ 
and absent in the IPOD. Accordingly, we assigned α -S inclusions to functionally different compartments, based 
on their colocalization with hsp70 and lmp2 in wild type SH-SY5Y cells (Fig. 4A), α -S-GFP SH-SY5Y cells (data 
not shown) and rat primary neuronal cells (see Supplementary Fig. S9). For all three α -S inclusion induction 
approaches both JUNQ and IPOD-deposits were identified, but distribution of α -S inclusions over these com-
partments differed. A significantly higher amount of JUNQ-deposits was obtained after the α -S monomer and 
α -S seed treatments, compared to the treatment with 5 nM rotenone. Only 4% of α -S inclusions found after treat-
ment with α -S monomers and 2% after treatment with α -S seeds appear to be IPOD-inclusion. In contrast, after 
treatment with rotenone, 54% of total inclusions studied showed characteristics of IPOD inclusions (Fig. 4B). 
Based on the juxtanuclear location of JUNQ- inclusions, we conclude that JUNQ- inclusion typically have a 
round or oval/kidney-like morphology (Fig. 3C). In the absence of conclusive immunostaining, location and 
morphology seem good parameters to assign α -S inclusion to IPOD and JUNQ.
Functionally different α-S inclusions might affect cellular survival. Long-term exposure to 5 nM 
rotenone leads to inclusion body formation in dopaminergic neurons of animal and human origin33. At higher 
concentrations, rotenone is very toxic (Fig. 5C, right panel). It inhibits the mitochondrial electron transport 
chain35, decreases proteasome activity and increases intracellular reactive oxygen species levels36. These elevated 
levels of reactive oxygen species were found to induce cellular proteins to form insoluble aggregates37. α -S aggre-
gation itself, e.g. induced by a high intracellular α -S concentration, has also been related to decreased viability 
and increased cytotoxicity32,38,39. We therefore compared the viability of cells, treated according to the different 
α -S inclusion induction protocols, and assessed the metabolic activity in MTT assays.
In the presence of 100 μM α -S monomers or 1 μM α -S seeds the uptake of PI, visualized after 72 hours, indi-
cates a decrease in viability. Note that almost all cells exposed to 1 μM α -S seeds detached from the surface, 
leaving hardly any adherent cells (Fig. 5A). Reducing the concentration to 500 nM α -S seeds kept considerably 
more of the α -S seed-treated cells attached (data not shown). Already after 24 hours, treatment with 100 μM α -S 
monomers or 500 nM α -S seeds resulted in a significant reduction in the metabolic activity (Fig. 5B). Treatment 
with high rotenone concentrations caused massive cell detachment (data not shown) and let to a 93% decrease 
in metabolic activity. In contrast, such a significant decrease in metabolic activity could not be detected upon 
treatment with the low rotenone concentrations. Even after 4 weeks in culture with 5 nM rotenone, we did not 
observe significant differences in metabolic activity compared to the control group (Fig. 5C). Treatment with α -S 
monomers, α -S seeds and rotenone leads to the formation of functionally different α -S inclusion. Accumulation 
of aggregated or aggregation prone proteins in JUNQ inclusions has been reported to be cytotoxic24. The observed 
Figure 4. α-S sequesters in IPOD and JUNQ- inclusions in SH-SY5Y cells. The ratio of IPOD to JUNQ is 
dependent on the induction method. (A) α -S inclusions are induced with 5 nM rotenone for 4 weeks in SH-
SY5Y cells. Immunostaining was performed for α -Salexa555 (cyan), lmp2alexa488 (green), hsp70alexa633 (red) and the 
nucleus was visualized using DAPI (blue). Based on protein colocalization, two different α -S inclusion types 
can be observed. hsp70 and lmp2 colocalize with α -S in JUNQ (top row, red arrows), in other α -S inclusions, 
no colocalization with these proteins can be observed and they are therefore categorized as IPOD (bottom 
row, green arrow); scale bar: 10 μm. (B) After treatment with 100 μM α -S monomers (N = 57) or 500 nM α -S 
seeds (N = 68) for 24 h, many JUNQs (96,5% and 98,5%) developed in cells. In contrast, after 5 nM rotenone 
treatment for 4 weeks, 54% of IPODs were observed (N = 54).
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differences in cytotoxicity of the α -S inclusion induction protocols might be directly related to the amount of 
JUNQ- and IPOD-inclusions obtained with these different methods, but stress factors may also play a role. 
Speculating that the amount and ratio of JUNQ- to IPOD–inclusions might have a significant effect on cellular 
survival in vitro24,34, we extended our approach to in vivo samples. Using the protocol for distinguishing JUNQ- 
from IPOD-inclusions in vitro, we tested whether similar differences in α -S inclusions can be observed in vivo. In 
diseased human brain tissue, many LBLI in the mesencephalon could be observed after immunolabelling for α -S 
Figure 5. α-S inclusion induction methods differ in cytotoxicity. The viability of α -S-GFP SH-SY5Y 
cells treated according to the 3 α -S inclusion induction protocols was assessed in viability and metabolic 
activity assays. (A) Exposure to 100 μM α -S monomers or 1 μM α -S seeds lead to decreased cell viability and 
detachment of α -S-GFP SH-SY5Y cells 72 hours after administration. (B) Administration of 100 μM α -S 
monomers and 500 nM α -S seeds resulted in a significant decrease in metabolic activity after 36 hours. (C) A 
low rotenone concentration of 5 nM in the medium did not have an effect on cell viability even after 4 weeks. 
In contrast, α -S-GFP SH-SY5Y cells treated with 100 μM rotenone for 36 hours show a significant decrease in 
metabolic activity; paired student’s t-test: *signifies a p-value < 0.05.
Figure 6. α-S sequesters in different LBLIs. Sample of mesencephalon of a patient suffering from clinical 
dementia (LB disease). (A) Immunostaining was performed for α -Salexa555 (cyan), lmp2alexa488 (green), 
hsp70Aalexa633 (red) and counterstaining was performed with DAPI. Judging LBLI colocalization with lmp2 and 
hsp70, both IPOD and JUNQ-LBLI can be observed. Whereas IPODs (lower row, indicated by green arrow) can 
become comparatively large, JUNQs (upper row, indicated by white arrow) are usually smaller and less dense; 
scale bar: 10 μm. (B) In the patient material many more IPODs (94%) than JUNQs were observed (N = 76).
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(data not shown). Additional immunolabelling for hsp70 and lmp2 showed, like for the in vitro cell model, two 
distinct types of α -S inclusions in this patient (Fig. 6A). The majority of the inclusions had IPOD characteristics 
(96%) whereas only a minor fraction could be characterized as JUNQ- inclusions (4%) (Fig. 6B).
Discussion
Amyloid deposits represent a hallmark of many neurodegenerative diseases2–10,40–42. Toxicity in these diseases 
has however often been attributed to oligomeric protein aggregates43–46. In that respect, it remains controversial 
whether the amyloid deposits themselves are toxic6,16–18,47–54. In some diseases, inclusion body formation seems 
neuroprotective. For example, studies on Huntington’s disease indicate that the formation of htt inclusion bodies 
reduced the soluble htt protein and enhanced neuronal survival54. On the other hand, in PD, inclusions induced 
in neurons resulted in propagation of pathological aggregates, selective decrease in synaptic proteins, progressive 
impairment of neuronal excitability and connectivity and eventually cell death55.
Whether inclusion body formation is toxic may depend on several factors. Misfolded proteins have been 
reported to sequester in different cell compartments23,34. Protein accumulation and aggregation in these com-
partments has been related to neurotoxicity24. Additionally, heterogeneity in inclusion body morphology, pro-
tein composition, density and location in the cell has been reported23,33,56–58. Here we show that the three tested 
induction methods result in α -S inclusions which differ in morphology, cellular location and colocalization with 
marker proteins. These marker proteins indicate that, depending on the induction method, the α -S inclusions can 
appear in different types of protein quality control (PQC) compartments. The toxicity of the induction methods 
seems to correlate with the distribution of α -S inclusions over these different compartments and we therefore 
hypothesize that the sequestration of α -S in specific compartments determines cell fate and disease pathology. 
However, in the experiments reported here we focused on three different methods with comparable amount of 
inclusion formation. The relation between the concentrations of the compounds used to induce inclusion forma-
tion, the types of α -S inclusions formed, and toxicity needs to be further investigated.
The treatment with α -S seeds and α -S monomers significantly reduced cell viability and metabolic activity 
(Fig. 5A,B). The mechanism by which α -S seeds affect cell fate is not fully understood. However, to serve as nucle-
ation points for α -S aggregation, α -S fibrils must be internalized and gain access to the cytoplasmic α -S mono-
mer pool. Short fibril fragments can enter the cytoplasm, as inclusions consisting of endogenous α -S are shown to 
originate from externally supplied α -S-fibril fragments (Fig. 1). This implies that α -S amyloid fibril fragments can 
propagate LB formation and may hence play an essential role in LB formation in vivo. In literature, this potential 
infectious mechanism has been discussed. α -S aggregation has been shown to propagate from mouse brain to 
grafted dopaminergic neurons and to seed aggregation in human cell cultures, indicating exchange of amyloid 
material or take up after release of amyloid deposits from dying or dead cells59,60.
Compared to the α -S inclusion induction method based on the addition of α -S fibril fragments, the con-
centration of α -S monomers used to induce intracellular protein aggregation was high. This relatively high α -S 
concentration was used to ensure monomer take up, to distort the well-regulated intracellular α -S concentrations 
and allow a fast formation of α -S inclusions. Although the concentrations used in the experiments are 2–4 times 
higher than the reported physiological α -S concentrations, elevated concentrations of α -S are observed in PD. 
It has been reported that in cases of familial PD with α -S gene locus triplication, the α -S monomer concentra-
tion in the brain was significantly higher than normal which can lead to protein aggregation61. Further, α -S was 
shown to be secreted to the extracellular space. There, it can activate and liberate microglia from the surrounding 
extracellular matrix, which is a hallmark for neuroinflammation62. Extracellular α -S can also be endocytosed by 
astrocytes, which express pro-inflammatory cytokines62. These responses could lead to increased stress levels 
in cultures and may lead to toxicity. At the monomer concentrations used, α -S was observed to aggregate in 
cell medium after 24–48 hours (see Supplementary Fig. S10). Hence, we cannot exclude the possibility that in 
the treatment with α -S monomers the induction of α -S inclusion formation, or the observed effect on viability 
and metabolic activity, results from α -S fibrils or oligomeric intermediates. However, toxicity depends on the 
particle concentration, not on the equivalent monomer concentration63. The particle concentration of the long 
fibrils in the medium is low compared to that of sonicated fibrils. Moreover, a comparable decrease of metabolic 
activity is observed when cells are treated with α -S-monomers at concentrations below the critical aggregation 
concentration64, indicating the existence of other, monomer dependent pathways. Of the three approaches used 
to induce the formation of α -S inclusions, the treatment with a low concentration of rotenone was least toxic. 
This treatment hardly affected the metabolic activity of the cells over weeks (Fig. 5C). Yet, a comparable number 
of cells containing α -S inclusions was found, indicating functional differences between α -S inclusions resulting 
from α -S monomer or α -S seed treatments compared to the low dose rotenone treatment.
Biochemically different inclusion bodies related to protein misfolding have been identified and described in 
yeast23,34,65 and mammalian cells24,34,66,67. To maintain protein homeostasis, misfolded or aggregated proteins need 
to be refolded, degraded or stored safely to avoid jeopardizing cellular survival. Misfolded proteins have been 
observed to localize to distinct PQC compartments depending on their solubility. When the proteasome system is 
saturated by increased protein load, misfolded soluble proteins are temporarily stored in the JUNQ compartment, 
while insoluble amyloid aggregates are sequestered in IPODs. In protein aggregation diseases, this localization to 
different PQC compartments has been related to neurotoxicity or neuroprotection. In these diseases, sequestra-
tion of misfolded or aggregated proteins in the JUNQ compartment can become toxic. The accumulation of many 
aggregation-prone proteins may clog the JUNQ compartment, and block the path to proteasomal degradation. 
Further, JUNQs can sequester chaperones, like hsp70, involved in protein refolding, leading to impairment of 
cellular protein homeostasis. Misfolded or aggregated proteins may accumulate in the cytoplasm and become 
toxic23,24,68.
In contrast to results reported for other proteins23, α -S was observed to accumulate in both IPOD and JUNQ 
compartments. The ratio of the distribution of α -S between these compartments depended on the induction 
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method (Fig. 4B). In agreement with the observed cytotoxicity, many JUNQ-inclusions and hardly any IPODs 
were observed shortly after treatment with α -S monomers or α -S fibrils. IPOD-inclusions were much more prev-
alent after the less toxic rotenone treatment. Induction of α -S inclusion formation with low concentrations of 
rotenone resulted in approximately equal amounts of JUNQ- and IPOD-inclusions.
When the cell’s internal stress level is moderate, the proteins are sequestered by the PQC to both compart-
ments. JUNQ inclusions only develop if the quality control machinery is compromised23,34. During the rotenone 
treatment, the cell viability is not affected, and we therefore conclude that cellular stress levels are low compared 
to treatment with α -S monomers and α -S seeds. We postulate that during rotenone treatment, the PQC is still 
partially active and proteins in the JUNQ can be refolded or degraded to some extent. Therefore fewer JUNQ 
inclusions form and more non-toxic IPOD-inclusions appear.
The results presented here support the hypothesis that in neurodegenerative diseases accumulation of aggrega-
tion prone proteins in the JUNQ compartment is toxic24. However, although accumulation of aggregated protein 
in the IPOD has been suggested to prevent hazardous interactions with the cellular proteome, IPOD-inclusions 
may still contribute to neurotoxicity by sequestering other proteins69, taking up space and blocking normal trans-
port pathways, especially within the narrow confines of the axons and dendrites (Fig. 2D).
The results obtained are not specific to the model system studied. The distribution of α -S over different PQCs 
observed in SH-SY5Y cells and primary neuronal cultures was also observed in tissue derived from a patient suf-
fering from LB disease. The majority of LBs in this patient’s brain tissue was immunoreactive for α -S, but not for 
hsp70 and lmp2. Only a minor fraction of < 5% could be assigned to the JUNQ-compartment. The large fraction 
of nontoxic IPOD-LBs in diseased tissue may result from the long time span between the onset of the disease and 
death. In time, cells containing toxic JUNQ inclusions will die. Hence, the relative number of cells containing 
inert and harmless IPOD inclusions is expected to increase. This suggests that when α -S is exclusively sequestered 
to IPOD-LBs it hardly affects cell viability.
In conclusion, our findings support a model for LB formation in which misfolded α -S can be sequestered to 
IPOD or JUNQ inclusion sites. We speculate that cellular stress levels determine the ratio of JUNQ to IPOD-LBs, 
which in turn directly affects cell viability and stage or progression of disease (Fig. 7). By preventing the induction 
of JUNQ-inclusions and the subsequent decline of the intracellular protein quality control, cell and tissue degen-
eration may be averted. The presented cell model system may offer an attractive platform to develop therapeutics 
that target the formation, inhibition, or degradation of toxic JUNQ inclusions.
Materials and Methods
Recombinant protein. Expression of human wild type α -S and the 140C mutant (α -S 140C) with a single 
alanine to cysteine substitution at residue 140 was performed in E. coli B121 (DE3) using a pT7 based expression 
system. For α -S, the N-terminus plays a critical role in membrane binding70. Attaching the GFP molecule to the 
C-terminal end of α -S minimizes interference with both membrane binding and amyloid forming properties of 
α -S71. Details on α -S purification procedure are described elsewhere72. Purified protein was stored at − 80 °C in 
Figure 7. The sequestering of misfolded proteins to specific internal PQC compartments is related to 
internal stress level and directly affects cell viability. Misfolded cytosolic proteins can either be refolded or 
degraded by proteins in the JUNQ compartment or stored in the IPOD. This sorting of misfolded proteins is 
managed by the PQC. (A) When misfolded proteins appear but the cell’s internal stress level is moderate, the 
proteins are sequestered by the PQC to both compartments: they are either processed or temporally stored 
in the JUNQ where active degradation or refolding prevents the formation of proteinaceous inclusions. 
Alternatively, they are sequestered to the IPOD where they form insoluble inclusions. IPOD inclusions are not 
directly toxic, but fibrils stored in the IPOD can seed protein aggregation in other cells. (B) Elevated stress levels 
increase the amount of misfolded, cytoplasmic proteins. Hence, more misfolded proteins are sequestered to 
the JUNQ compartment and may saturate and exhaust the quality control machinery. The JUNQ compartment 
clogs, and protein degradation or refolding is impaired. Cytotoxic proteinaceous inclusions are formed in 
the JUNQ, this toxicity may arise from sequestration of other proteins involved in managing and processing 
misfolded proteins (e.g. hsp70) and accumulation of misfolded or aggregated protein in the cytoplasm23.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:23116 | DOI: 10.1038/srep23116
aliquots until further use. α -S A140C monomers were conjugated with AlexaFluor350 maleimide following the 
manufacturer’s labelling protocols (Life Technologies, USA). For expression of GFP with a poly-histidine (HIS) 
tag, α -S with GFP-HIS tag and α -S with HIS tag, pET28A constructs were used. The constructs were expressed in 
E. coli, extracted and purified on a Ni-NTA column (Invitrogen, USA) (see Supplementary Fig. S1).
Production of α-S fibrils and seeds. To produce short α -S fibrils that can seed aggregation, 100 μM α -S 
monomers were assembled into fibrils in aggregation buffer (100 mM NaCl, 50 mM Tris-HCl pH 7.4, 5 μM ThioT, 
0.005% NaN3) at 37 °C under constant agitation (950 rpm) in a plate reader (Infinite 200 PRO multimode, Tecan 
Ltd., Switzerland). In the plate reader, fibril growth was followed by monitoring ThioT fluorescence (excitation 
446 nm, emission 485 nm), the reaction was stopped at maximal fluorescence intensity after 5 days. The obtained 
α -S fibrils were dialyzed (Slide-A-Lyzer G2 Dialysis Cassettes, 10K MWCO, Pierce, USA) against 2 l of PBS 
containing 1% penicillin and streptomycin for 24 hours at 4 °C. Subsequently, fibril fragments were produced 
by sonicating the fibrils with a tip sonicator (Sonifier 250, Branson Ultrasonics Corporation, USA) on ice for 
3 min. The thus obtained α -S seeds were visualized by AFM (see Supplementary Fig. S5A), aliquoted and stored 
at − 80 °C until use. To test the ability of obtained α -S seeds to nucleate aggregation of a monomeric α -S pool, 
500 nM α -S seeds were added to a solution of 25 μM α -S monomers in F-Buffer (10 mM Tris-HCl pH 7.4, 2 mM 
MgCl2, 1 μM CaCl2, 0.2 mM DTT, 0.5 mM ATP, 1M KCl) including 5 μM ThioT on a plate reader under constant 
agitation. The aggregation was stopped after 24 hours at maximum ThioT fluorescence (see Supplementary Fig. 
S5B). To assemble α -S-GFP or α -S 140Calexa350 fibrils, we used the same protocol. 100 μM protein (ratio 1:10 of 
α -S-GFP or α -S 140Calexa350 and α -S) was incubated in aggregation buffer (10 mM NaCl, 10 mM Tris-HCl pH 
7.4, 0.1 mM EDTT pH 7.4) for 5 days under constant shaking (500 rpm) at 37 °C. To visualize the α -S-GFP fibrils, 
the protein-buffer solution was diluted 1:10 in PBS. Total internal reflection (TIRF) microscopy images were 
obtained by using a Nikon Ti Eclipse inverted microscope with PlanFluor 60x Ph1 DLL objective (Nikon, Japan) 
(see Supplementary Fig. S2).
Atomic Force Microscopy. AFM samples were prepared by adsorbing 100 nM of α -S seeds on freshly 
cleaved mica for 4 min, followed by 2 washes with 100 μl of deionized water. The samples were dried under nitro-
gen gas passed through a 0.22 μm filter. AFM images were acquired on a Bioscope Catalyst (Bruker, Santa Barbara, 
CA, USA) in tapping mode using a silicon probe, NSC36 tip B with force constant of 1.75 N/m (MikroMasch, 
Tallin, Estonia). All images were captured with a scan rate of 0.5 Hz.
STED microscopy. Stimulated emission depletion (STED) microscopy73 was employed for subdiffraction 
resolution fluorescence imaging on a custom-made setup. The system’s implementation is based on a supercon-
tinuum laser source, and similar to the setup described elsewhere74. It is capable of acquiring one channel with 
confocal and two channels with STED resolution quasi-simultaneously. The supercontinuum laser source was 
a SC450-PP-HE system running at 1 MHz, manufactured by Fianium Ltd, UK. For beam-scanning, we used 
a YANUS IV scan head from Till Photonics, Germany. The objective was a Leica 100x/1.4. For imaging GFP, 
Alexa Fluor® 594 and Alexa Fluor® 647, we used excitation/emission wavelengths of 488 ± 3 nm/520 ± 14 nm, 
586 ± 7 nm/624 ± 40 nm and 637 ± 5 nm/ 685 ± 20 nm, respectively, using optical filters from AHF, Germany. The 
STED wavelengths for Alexa Fluor® 594 and Alexa Fluor® 647 were set to 720 ± 10 nm, and 750 ± 10 nm, respec-
tively. Beam powers for acquisition were 1–5 μW for the excitation beams, as measured in front of the objective. 
STED beam powers amounted to 1–2 mW. To reduce crosstalk, pulses for various channels were separated in time 
by varying optical path lengths. A home-built electronic gating device transmitted detector signals occurring at 
the correct time to the acquisition hardware, and rejected crosstalk signals occurring at other times. Dichroic 
mirrors and filters were purchased from AHF, Germany.
Cell culture, transfection and selection of SH-SY5Y cells. SH-SY5Y cells were grown in proliferation 
medium, a 1:1 mixture of Ham’s F12 medium including Gibco® GlutaMAX™ and GIBCO® EBSS supplemented 
with 10% heat inactivated FBS and 1% Penicillin/Streptomycin. All SH-SY5Y cells used in experiments were dif-
ferentiated into post-mitotic, neuron-like cells with extended dendrites and expressing neuronal marker proteins 
as described elsewhere75. In short, for differentiation, we seeded SH-SY5Y cells to 60% confluency and induced 
differentiation by adding starvation medium containing 1% FBS and 10 μM retinoic acid for 7 days. All chemicals 
were obtained from Invitrogen, USA if not indicated differently.
SH-SY5Y cell lines stably expressing α -S-GFP (α -S-GFP SH-SY5Y) were established to visualize intracel-
lular α -S. For transfection, SH-SY5Y cells were seeded, grown until 30–50% confluency, and transfected with 
pEGFP-N1-α -S. DNA (250 ng/cm2) was diluted in Opti-MEM in reduced Serum medium (GIBCO® ) including 
Lipofectamine® LTX Reagent with PLUS™ Reagent. The mix was incubated for 5 minutes at room tempera-
ture before adding Lipofectamine LTX. For every 250 ng of DNA, 0.5 μl of Lipofectamine LTX and 0.19 μl of 
Lipofectamine PLUS reagent were mixed, according to manufacturer’s protocol. After Lipofectamine LTX addi-
tion, a 30 minutes incubation at room temperature was performed. The medium of the cells was changed and 
the DNA, Lipofectamine LTX, and Lipofectamine® LTX Reagent with PLUS™ Reagent mix were added. After 
one day, the medium was changed to proliferation medium. Two days after transfection, cells were trypsinized 
and re-seeded in conditioned medium (1 part filtered old proliferation medium and 2 parts fresh proliferation 
medium). The next day, G418 (500 μg/ml) was added and cells were grown in G418 supplemented conditioned 
medium until selection by FACS analysis. GFP-positive cells were expanded in culture dishes and stocks were 
stored in liquid nitrogen. For the western blot in Figure S4, SH-SY5Y cells and GFP SH-SY5Y cells they were 
lysed in SDS sample buffer containing 0,1M DTT. After 5 minutes boiling and 2 minutes spinning at maximum g, 
samples were loaded and separated on a 12% SDS PAGE gel. The blot for α -S detection was, prior to blocking in 
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5% NFDM in TBS + 0.3% tween, first fixed in 0.4% PFA in PBS to improve detection. The antibody used for α -S 
was obtained from BD biosciences (nr610786). For the visualization of α -S, a shorter exposure and longer time 
of the same blot was used and compared. For GFP detection a polyclonal antibody raised in rabbit against GFP 
(Invitrogen A11122) was used, to visualize GAPDH the antibody sc-32233 from Santa Cruz was used.
Primary neuron extraction and culture. The extraction and culturing of primary neuronal cells was per-
formed as described elsewhere76. In short, cells were obtained from new born (P1) Wistar rat pups. Both (cortical) 
cerebral hemispheres were isolated in a sterile environment, minced and trypsinized. The minced hemispheres 
where dissociated by trituration after which the cells were ready to be plated on polyethylenimine-coated culture 
dishes (Acros Organics, USA) with glass bottoms or polyethylenimine coated coverslips (Sigma-Aldrich, USA) 
to 60% density. After 2 hours, adhered cells were washed with DMEM (Invitrogen, USA) and cultured in 900 μl 
serum and antibiotics-free R 12 medium77 at 37 °C with 5% CO2. All research involving animals has been con-
ducted according to Dutch law (as stated in “Wet op de dierproeven”), and approved by DEC, the Dutch Animal 
Use Committee.
α-S inclusion formation, -quantification and determination of nuclear proximity. The forma-
tion of α -S inclusions was initiated by: i) exposure to 100 μM α -S monomers, ii) exposure to 500 nM α -S seeds 
both for 24 hours, followed by a 4 day incubation in starvation medium and iii) exposure to 5 nM rotenone for 28 
days. Cells were labelled for α -Salexa594 and phalloidinalexa647. The cell nuclei were visualized with DAPI. Labelled 
cells containing α -S inclusions were imaged using confocal microscopy (LSM 510, Zeiss, Germany). The α -S 
inclusions morphologies were classified and divided in round, oval-kidney like, amorphous or hairy. To make 
this classification possible the laser intensities and thresholds were adjusted in a way that for each sample the full 
range of possible intensities was covered and no over- or under saturated pixels were present. To be considered 
for shape classification the α -S inclusions had to be larger than 0.5 μm. In our shape classification we considered 
α -S inclusions to be 1) Oval, if the inclusion had sharp boundaries and one elliptical axis that was at least 1.5 
times as long as the other. 2) Round, if the inclusions had sharp boundaries and one elliptical axis was less than 
1.5 times as long as the other. 3) Hairy, if the inclusions had at least three evaginations with a length > 1 μm and a 
width < optical resolution. 4) Amorphous, if the inclusions did not have well defined boundaries. Nuclear prox-
imity was evaluated by ascertaining the distance of α -S inclusions to the nucleus; inclusions whose distance to 
the nucleus was smaller than their diameter (longest inclusion axis + shortest inclusion axis)/2) were classified 
as juxtanuclear.
Immunocytochemistry, ThioS and phalloidin staining. Cell samples were washed with PBS and fixed 
in 3.7% paraformaldehyde/PBS solution. For immunolabelling, cells were permeabilized with 0.3% Triton X-100 
and 0.1% BSA in PBS. Autofluorescence was quenched with 50 mM NH4Cl in PBS. Thereafter, primary antibodies 
(Table 1) were diluted 1:100 in goat serum dilution buffer (16% goat serum, 0.3% Triton X-100, 0.3 M NaCl in 
Antibody Epitope Host species Source
α -S 15–123 mouse BD biosciences
α -S 123–140 guinea pig Abcam
α -S 96–140 rabbit Santa Cruz Biotechnology
α -S pSer129 Ser 129 rabbit Santa Cruz Biotechnology
20S LMP2 lmp2 rabbit Stressgen
hsp70 hsp70 mouse Abcam
GFP GFP rabbit Invitrogen
GAPDH GAPDH mouse Invitrogen
Table 1.  Primary antibodies.
Host Anti Conjugate Source
goat mouse HRP Sigma
goat mouse Alexa488 Invitrogen
goat mouse Alexa555 Invitrogen
goat mouse Alexa594 Invitrogen
goat mouse Alexa633 Invitrogen
goat rabbit Alexa488 Invitrogen
goat rabbit Alexa555 Invitrogen
goat rabbit Alexa633 Invitrogen
goat rabbit HRP Invitrogen
goat guinea pig Alexa555 Invitrogen
Table 2.  Secondary antibodies.
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PBS) and incubated overnight. The next day, cells were washed 3 times with 0.3% Triton X-100 and 0.1% BSA in 
PBS at room temperature and the appropriate secondary antibodies (Table 2) were diluted 1:100 in 0.3% Triton 
X-100 and 0.1% BSA in PBS and incubated for 1 hour. For ThioS or phalloidin staining, fixed cells were incubated 
with 0.05% ThioS or 70 nM phalloidinalexa647 in PBS for 15 minutes. Nuclear counterstaining was performed by 
incubation in 300 nM 4′ ,6-diamidino-2-phenylindole (DAPI) in PBS for 10 minutes. After washing with PBS, 
samples were mounted with mounting medium (ibidi, Germany).
Confocal Microscopy. Confocal laser scanning microscopy images were obtained using a LSM510 Confocal 
microscope with an 63 × oil immersion objective (NA = 1.4, Zeiss, Germany) with appropriate laser lines (Argon 
laser (488 nm), Helium-Neon laser (543 nm), Argon ion laser (633), Chameleon pulsed laser (340 nm, Coherent, 
USA). Images were taken successively. Emission was detected using appropriate dichroic mirrors and filter sets. 
Images were analyzed with the ZEN software 2009 (Zeiss, Germany).
Histology. For Eosin-haematoxylin staining (HE), α -S-GFP SH-SY5Y cells were grown on cover glasses 
coated with collagen IV. Subsequently cells were fixed in a 0.4% PFA in PBS solution. Samples were washed and 
stained with eosin followed by haematoxylin, mounted with mounting medium (ibidi Germany) and imaged 
(E600, Nikon, Japan).
A biopsy of human mesencephalon derived from a patient diagnosed for LB disease was dehydrated in an 
increasing ethanol series, embedded in paraffin and cut in 5 μm sections. After rehydration, the sections were 
treated with formic acid and heated to 97 °C for 10 minutes in TRS buffer (Dako) followed by a treatment with 3% 
H2O2. Samples were immunostained for α -Salexa555, hsp70alexa633 and lmp2alexa488 (Tables 1 and 2). DAPI was used 
as counterstaining.
Immunoblot analysis. Cells were seeded and grown to 60% confluency and differentiated in T25 cul-
ture flask (Greiner, Germany). Cells were then lysed [4× Laemmli buffer (8% SDS, 240 mM Tris-Cl, pH 6.8), 
100 mM DTT] for 15 minutes at room temperature, scraped and transferred to Eppendorf tubes. Lysates were 
sonicated, boiled for 5 minutes and centrifuged for 2 minutes at 12000 rcf (IEC MicroMAX tabletop centri-
fuge). Cleared lysates were separated on a SDS-PAGE gel (12%) and blotted onto methanol activated PVDF 
membrane (Millipore, USA). For improved α -S detection, membranes were first fixed in a 0.4% PFA in PBS 
solution, then blocked in non-fat-dried-milk (5% ELK, Campina) in TBS and Tween-20 (0.3%) and incu-
bated overnight at 4 °C with primary antibody against α -S or GAPDH. Primary antibodies were detected by 
goat-anti-mouse-HRP conjugated antibodies [1:8000 in TBS + tween-20 (0.3%)]. Protein Marker bands were 
visualized by Strep-Tactin-HRP [1:5000 in TBS + tween-20 (0.3%)] (Bio-Rad, USA). HRP-conjugated protein 
bands were detected by Clarity Western ECL Substrate (BioRAD, USA) and imaged on a FluorChem M imager 
(Protein Simple, USA).
Viability and Metabolic activity assay. Cells were seeded in either flow channels for the viability assay 
(μ-slide I, ibidi Germany) or 24-well plates (Greiner Bio-One GmbH, Germany) for the metabolic activity assay, 
grown to 60% confluency and differentiated. For the viability assay, cells were incubated with 100 μM α -S mon-
omers or 1 μM α -S seeds for 72 h. The viability assay was performed according to manufacturer’s instructions 
(Invitrogen, USA). In short, cells were washed with cold PBS and incubated with 100 μl/mL solution of propidium 
iodide (PI) for 15 minutes at room temperature. Subsequently, cells were washed with binding buffer. Images were 
obtained using an inverted fluorescence microscope (EVOS, AMG, USA).
For the metabolic activity assay, cells were incubated with 100 μM α -S monomers or 500 nM α -S seeds for 
24 hours, 5 nM rotenone for 28 days, or 100 μM rotenone for 36 hours. Next, cells were treated with 0.5 mg/ml 
MTT (Invitrogen, USA) in medium for 4 hours at 37 °C in an atmosphere of 5% CO2. Before the medium was 
withdrawn carefully and discarded, detached cells were removed via gentle centrifugation (500 × g, 5 min) and 
included in the metabolic activity assay. After cell solubilization with DMSO, metabolic activity was quantified on 
a multiwell scanning plate reader by measuring the absorbance at 540 nm with background subtraction at 690 nm 
(Tecan Ltd, Switzerland).
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